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Wound healingCellmotility is a highly dynamic phenomenon that is essential to physiological processes such asmorphogenesis,
wound healing and immune response, but also involved in pathological conditions such asmetastatic dissemina-
tion of cancers. The involvement of the molecular chaperone TRAP1 in the regulation of cell motility, although
still controversial, has been recently investigated alongwith somewell-characterized roles in cancer cell survival
and drug resistance in several tumour types. Among different functions, TRAP1-dependent regulation of protein
synthesis seems to be involved in the migratory behaviour of cancer cells and, interestingly, the expression of
p70S6K, a kinase responsible for translation initiation, playing a role in cell motility, is regulated by TRAP1. In
this study, we demonstrate that TRAP1 silencing enhances cell motility in vitro but compromises the ability of
cells to overcome stress conditions, and that this effect is mediated by the AKT/p70S6K pathway. In fact:
i) inhibition of p70S6K activity speciﬁcally reducesmigration in TRAP1 knock-down cells; ii) nutrient deprivation
affects p70S6K activity thereby impairing cellmigration only in TRAP1-deﬁcient cells; iii) TRAP1 regulates the ex-
pression of both AKT and p70S6K at post-transcriptional level; and iii) TRAP1 silencingmodulates the expression
of genes involved in cell motility and epithelial–mesenchymal transition. Notably, a correlation between TRAP1
and AKT expression is found in vivo in human colorectal tumours. These results provide new insights into TRAP1
role in the regulation of cell migration in cancer cells, tumour progression and metastatic mechanisms.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
TRAP1 (Tumour Necrosis Factor Receptor-Associated Protein 1) is a
molecular chaperone, member of the HSP90 family, that contributes to
survival of cancer cells and is induced in most tumour types [1]. Recent
reports have shown that TRAP1 stays at the crossroad ofmultiple crucial
processes in the onset and progression of the malignant phenotype.
Indeed, TRAP1: i) controls protein homeostasis through a direct1;HSP, heat shock protein; KD,
l carcinoma; EMT, epithelial–
; GAPDH, glyceraldehyde-3-
interfering RNA.
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translational degradation [2]; ii) contributes to tumour cell bioenergetic
regulation through the control of mitochondrial respiratory complexes
[3–5]; iii) is part of a pro-survival signalling pathway aimed at evading
the toxic effects of oxidants and anticancer drugs and protects mito-
chondria against damaging stimuli via a decrease of ROS generation
[6]. Since elevated ROS are reported to stimulate cell invasion [7],
Yoshida and colleagues [4] evaluated whether TRAP1 expression
might affect this phenotype by transwellmigration assays. Interestingly,
they demonstrated that TRAP1 knockout or transient suppression dra-
matically enhances cell invasiveness, both in mouse ﬁbroblasts and in
a variety of human cell lines. The authors hypothesize that the contribu-
tion of TRAP1 to this phenotypemay be attributed, at least in part, to its
impact on cellular bioenergetics. By contrast, TRAP1-directed tumour
cell metabolism has been proposed as a pivotal mediator of tumour
cell motility and invasion in conditions of nutrient withdrawal [8]. In
this view, mitochondrial HSP90-directed bioenergetics could represent
an adaptive mechanism overcoming the global tumour-suppressive
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it is normally impaired. Interestingly, recent studies reported that tran-
sient TRAP1 silencing in cancer cells was associated with up-regulation
of a number of cell motility and metastasis-associated genes, whereas
TRAP1 overexpression was correlated with increased expression of
genes associated with cell proliferation [9,10]. However, the impact of
TRAP1 expression on transcriptional regulation of such genes may be
independent from its involvement in metabolic regulation and still
requires investigation. Moreover, high TRAP1 expression has been re-
cently associated with increased risk of lymph node metastasis in
esophageal squamous cell cancer (ESCC) andwith enhanced cell migra-
tion and invasion in ESCC cells through the STAT3/MMP2 signalling
pathway [11]. Noteworthy, despite a predominant mitochondrial local-
ization, we have also demonstrated the presence of TRAP1 on the cyto-
plasmic side of the endoplasmic reticulum (ER) [12], where it is
associatedwith ribosomes and several translation factors [2] in colorec-
tal carcinoma (CRC) cells, and protects from ER stress in breast cancers
[13,14]. This functionally yields a TRAP1-dependent attenuation of glob-
al protein synthesis through the downregulation of the p70S6K transla-
tion activation pathway [15]. Accordingly, TRAP1 silencing sensitizes
cells to the effects of novel antitumoural drugs that inhibit cap-
dependent translation such asRibavirin or 4EGI-1, resulting in increased
sensitivity to apoptosis [2] and reduced cellmotility [15] in TRAP1 inter-
fered cells upon treatment. These data show that TRAP1-dependent at-
tenuation of protein synthesis, although reducing the maximum
migratory capacity, enables cells to migrate under conditions of meta-
bolic stress. Interestingly, activation of p70S6K, a downstream target
of AKT, has been implicated in the regulation of cell motility at different
levels [16]. In ovarian cancer, where the PI3K/AKT/p70S6K pathway is
frequently activated, p70S6K has been considered a critical regulator
of the actin cytoskeleton in the acquisition of the metastatic phenotype
[17]. More speciﬁcally, in this studymodel, depletion of p70S6K expres-
sion or inhibition of its activity resulted in reduced migration.
Herein we demonstrate that TRAP1 controls the migratory potential
of cancer cells by regulating the AKT/p70S6K axis and inﬂuencing tran-
scriptional expression of several genes involved in cell motility. Of note,
we show that some of these features are conserved in CRC human
specimens.2. Materials and methods
2.1. Cell culture
Human HCT116 colon carcinoma cells and HEK293 embryonic
kidney cells were purchased from American Type Culture Collection
(ATCC) and cultured in DMEM containing 10% fetal bovine serum,
1.5 mmol/L glutamine, penicillin and streptomycin. Cell lines are rou-
tinely monitored in our laboratory by microscopic morphology check.
The authenticity of the cell lines was veriﬁed 1 year ago starting this
study by STR proﬁling, in accordance with ATCC product description.
TRAP1-stable interfered cells were obtained by sh-RNAs as described
previously [12].2.2. Plasmid generation and transfection procedures
Full-length TRAP1 and mutant Δ1-59-Myc were obtained as de-
scribed in [12]. Transient transfection of DNA plasmids was performed
with the Polyfect Transfection Reagent (Qiagen) according to the
manufacturer's protocol. TRAP1 transient silencing was performed
with siRNAs purchased from Qiagen (TRAP1: cat. no. SI00115150). For
control experiments, cells were transfected with a similar amount of
scrambled siRNA (Qiagen; cat. no. SI03650318). Transient transfections
of siRNAs were performed using HiPerFect Transfection Reagent
(Qiagen) according to the manufacturer's protocol.2.3. WB analysis
Equal amounts of protein from cell lysates and tumour specimens
were subjected to SDS-PAGE and transferred to a PVDF membrane
(Millipore).Where indicated, protein levels were quantiﬁed by densito-
metric analysis using the software ImageJ [18]. The following antibodies
were used for WB and immunoﬂuorescence: anti TRAP1 (sc-13557),
anti-β-actin (sc-69879), anti-GAPDH (sc-69778), anti-PI3K (sc-423)
and anti-p70S6K (sc-230) from Santa Cruz Biotechnology; anti-
phospho-AKT (Thr308) (#9275S), anti-AKT (#9272), anti-phospho-
eIF4B (#3591) and anti-phospho-p70S6K (#9205) from Cell Signaling;
anti-E-Cadherin (610404) and anti-paxillin (6100052) from BD biosci-
ences; phalloidin–tetramethylrhodamine B isothiocyanate (P1951)
from Sigma; and anti-SNAI1 (GTX100754) from Genetex. AKT isoforms
were detected by using the Akt Isoform Antibody Sampler Kit (#9940,
Cell Signaling).
2.4. RNA extraction and real-time RT-PCR analysis
RNA extraction procedures were performed as described in [12].
The following primers were used for PCR analysis. TRAP1: forward 5′-
GACGCACCGCTCAACAT-3′, reverse 5′-CACATCAAACATGGACGGTTT-3′;
GAPDH: forward 5′-AGGCTGAGAACGGGAAGC-3′, reverse 5′-CCATGG
TGGTGAAGACGC-3′; AKT1: forward 5′-CAGGATGTGGACCAACGTGA-3′,
reverse 5′-AAGGTGCGTTCGATGACAGT-3′; AKT2: forward 5′-ACAAGG
AAAGGGAACCAGCG-3′, reverse 5′-GGTACGCTGTCACCTAGCTC-3′; AKT3:
forward 5′-GAGGGGAGTCATCATGAGCG-3′, reverse 5′-ACTGGCATTTTG
CCACTGAA-3′; SOX4: forward 5′-AACATGACAGGCACTAGGACG-3′, re-
verse 5′-ATATTGCACAGGATGGATGGC-3′; F3: forward 5′-TGGAAATTCA
AAACAATTGGCAAAC-3′, reverse 5′-AGCATATTAGGAAGGTGCCCA-3′;
PRSS3: forward 5′-AGCTTTGGTGCTGACTACCC-3′, reverse 5′-AGGCTTTA
CACTCAGCCTGG-3′; E-Cadherin: forward 5′-CAGCCTGTCGAAGCAGGA
TT-3′, reverse 5′-TCATCCTCTGGGGGCAGTAA-3′; Snail: forward 5′-CGAG
TGGTTCTTCTGCGCTA-3′, reverse 5′-GGGCTGCTGGAAGGTAAACT-3′.
When possible, primerswere designed to be intron-spanning. The reac-
tion conditions were 95 °C for 5 min followed by 45 cycles of 15 s at
95 °C and 1 min at 60 °C. GAPDH was chosen as the internal control.
2.5. Time-lapse microscopy and image acquisition
Images from different samples have been acquired by using the Zeiss
Cell Observer system, as reported in [19]. In brief, the system is equipped
with phase contrast optics and provides an incubator chamber to control
the temperature (maintained at 37 °C) and CO2 percentage (maintained
at 5%) for extended observation of living cells. Within this work, digital
frames were acquired as 16 bit images of 650 × 514 pixels.
2.6. Wound healing assay
In order to study the dynamics of wound closure, cells were seeded
inmonolayer by plating in 12-well plates 200,000 cells/well in complete
medium; 24 h after plating the cell layer was scratched with sterile pi-
pette tip. Wound healing was followed for 24 h by acquiring digital
frames at 10 min intervals with an objective 10× (scale 0.767 pixel/μ).
PF4708671 (20 μM), LY294002 (10 μM) or PIK90 (0.5 μM) was used to
pre-treat cells for 1 h; Gln deprivation was performed for 16 h before
wound. Quantitative analysis of wound invasion by cell populations lo-
cated at the border was performed bymeasuring the gap area at 2 hour
intervals for 24 h (T0–T24h). The gap area was deﬁned by using the
wand tool in ImageJ (National Institute of Health, USA) and manually
reﬁning the selection in the presence of gross errors. The occupation
rate of empty space was evaluated as the ratio between average
distance between the two edges at each time point (Lti) and the same
distance immediately after the scratch (Lt0). LY294002 was purchased
by Calbiochem (Catalog No 440202), PF4708671 by Santa Cruz Biotech-
nology (sc-361288) and PIK90 by Selleck (S1187).
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sh-TRAP1 and scramble HEK293 or HCT116 cells, plated on cover-
slips, were washed once with PBS 1×, ﬁxed with 0.1 M phosphate
buffer containing 4% (w/v) paraformaldehyde for 15min, permeabilized
for 5minwith Triton X-100 (0.2% v/v in PBS) and incubated for 1 hwith
PBS 1× containing FBS (1% v/v) to bind to any remaining sticky places.
For paxillin detection, samples were stained by 1 hour incubation with
mouse antipaxillin mAbs (clone 349 from BD Biosciences), 1:25 in PBS
1×, and washed with PBS 1×. For E-Cadherin detection, samples
were stained by 1 hour incubation with anti-E-Cadherin (610404 BD
Bioscience) 1:100 in PBS 1×, and washed with PBS 1×. Coverslips
were then incubated with goat anti-mouse Alexa Fluor 568 antibody
(Invitrogen cod. A11004) 1:200 in PBS 1×. To visualize actin cytoskele-
ton coverslips were incubated with 0.1 μg/ml of phalloidin
tetramethylrhodamine-B-isothiocyanate (Sigma) for 1 h in a dark and
wet place. The coverslips were mounted in Mowiol 4-88 (Calbiochem,
CA) on glass slides. Immunoﬂuorescence studies were performed
by using a Carl Zeiss LSM700 confocal laser-scanning microscope.
Fluorescence images were acquired by using a laser line at 555 nm
and Plan-NeoFluar 40× oil objective.
2.8. Gene expression analysis
Gene expression analysis was obtained as described in [10].
2.9. Patients
Tumour and normal, non-inﬁltrated peritumoural mucosa were
obtained from 14 patients with CRC during surgical removal of the
neoplasm. Samples were divided into 125 mm3 pieces: one specimen
was ﬁxed in formalin and used for the histopathological diagnosis,
while the others were immediately frozen in liquid nitrogen and
stored at −80 °C for immunoblot analysis. Express written informed
consent to use biological specimens for investigational procedures
was obtained from all patients. In order to compare expression levels of
TRAP1, AKT and phosphor-AKT in different tumour specimens, pro-
tein levels were quantiﬁed by densitometric analysis using the
Quantity One 4.5.0 software (BioRad Laboratories GmbH, Segrate,
Italy) and expressed as time increase/decrease in tumours compared
to the levels in the respective peritumoural non-inﬁltrated mucosa
(Supplementary Table 1). TRAP1 expression levels were regarded as
being up-regulated if they had increased at least threefold in compari-
son to the corresponding non-inﬁltrated peritumoural mucosa.
2.10. Statistical analysis
The χ2-test was used to establish statistical correlation between the
expression levels of TRAP1 and those of AKT/phospho-AKT in human
CRCs. The paired Student t-test was used to establish the statistical sig-
niﬁcance between different levels of gene expression in TRAP1 cells
compared with related scramble controls.
3. Results
3.1. TRAP1 expression affects cell migration
Wehave previously demonstrated that p70S6K expression and glob-
al protein synthesis are under TRAP1 control, and that this is relevant for
themigratory behaviour of cancer cells [15]. To further characterize the
molecular environment and players of TRAP1 regulation, we focused on
PI3K/AKT/p70S6K pathway and analysed their involvement in the mo-
tility of TRAP1 knock down (KD) HEK293 cells compared to controls.
Cell migration has been studied during wound healing experiments
and quantitatively evaluated in terms of occupation rate of empty
space (see Materials and methods). According to our previous results,we show that, under basal conditions, sh-mediated TRAP1 silencing
(sh-TRAP1) results in increased migration in wound healing assays
(Fig. 1A and E); however, treatment with the p70S6K inhibitor
PF4708671 selectively reduces the rate of edge advancement of sh-
TRAP1 HEK293 cells, whereas scramble cells are unaffected (Fig. 1B).
The empty space occupation rate is plotted as a function of time in the
graph of Fig. 1C, where the curve for sh-TRAP1 PF4708671-treated cells
(red curve, open symbols) consistently runs above the curve for untreated
cells (closed symbols), whereas the curves for treated and untreated
scramble cells (blue curves) run together. Treatment with LY294002, a
PI3K inhibitor, reduces wound healing progression of sh-TRAP1 cells
(Fig. 1F) and also of scramble cells, even if at a lower extent; treatment
with LY294002 makes the scramble and sh-TRAP1 curves similar, as re-
ported in the graph 1G (see red and blue curves with open symbols). In
order to exclude side effects of LY294002 on other molecules upstream
p70S6K such as mTORC1, the migration during wound healing of scram-
ble and sh-TRAP1 cells has been also studied after treatment with PIK90,
a more speciﬁc PI3K inhibitor. The obtained results are collected in
Supplementary Fig. 1where it is shown that PIK90, as LY294002, impairs
cell migration of sh-TRAP1 and, less markedly, also of scramble cells.
These ﬁndings suggest that TRAP1 silencing enhances cell migration
downstream PI3K through the AKT/p70S6K axis, thus making these
cells addicted to such pathway. Consistently, sh-TRAP1 cells show
higher sensitivity to PF4708671 treatment than their scramble counter-
part, as suggested by reduction of phosphorylation levels of the speciﬁc
p70S6K downstream target eIF4B (Fig. 1D).
3.2. Regulation of PI3K/AKT/p70S6K pathway by TRAP1 in vitro and in CRC
human specimens
We have recently demonstrated that TRAP1 silencing induces an in-
crease of p70S6K protein expression and a consequent increase of phos-
phorylated p70S6K [15]. Therefore, we analysed other upstreamplayers
of the PI3K/AKT pathway, in order to further “dissect” TRAP1 contribu-
tion to this regulation. Notably, we show an increased expression of
AKT upon TRAP1 KD in two different experimental systems: HCT116
CRC cells and HEK293 cells; consequently, phosphorylated AKT protein
also increased in low TRAP1 background (Fig. 2A). Conversely, PI3K pro-
tein expression levels are not affected by TRAP1modulation, in keeping
withwound healing assays performed in the presence of PI3K inhibitors
(Fig. 1F and Supplementary Fig. 1). These data suggest that TRAP1 inﬂu-
ences this pathway downstream PI3K, through the regulation of AKT
and p70S6K expression. Interestingly, immunoblots performedwith an-
tibody speciﬁcally directed against single AKT isoforms show that the
expressions of AKT2 and AKT3 are the most up-regulated upon TRAP1
KD, thus contributing to the regulation of total AKT (Supplementary
Fig. 2). To analyse the nature of this regulation, i.e., if TRAP1 control
is at transcriptional/post-transcriptional level, qPCR experiments
were performed in stable (sh-mediated) KD cells (HCT116 and
HEK293) (Fig. 2B). Results show that TRAP1 expression does not affect
single AKT isoform mRNA levels and therefore TRAP1-dependent con-
trol of AKT (this study) and p70S6K [15] occurs at post-transcriptional
level. Of note, the transfection of a myc-tagged TRAP1 construct in
both sh-TRAP1 cells and scramble controls is able to reduce AKT protein
levels, partially rescuing the original phenotype (Fig. 2C); this ﬁnding
further conﬁrms the speciﬁcity of TRAP1 role in the regulation of AKT
expression. Interestingly, the observed effect is even higher after
transfection of theΔ1-59-TRAP1 deletionmutant, which lacks themito-
chondrial targeting sequence and is therefore unable to entermitochon-
dria [12], supporting the evidence that this regulation is due to the
extramitochondrial-localized TRAP1.
Noteworthy, a correlation between TRAP1 and AKT/phospho-AKT
levels was conﬁrmed in human colorectal cancer specimens (Fig. 2D).
To this purpose, we analysed our tissue collection of CRCs, previously
characterized for the expression of TRAP1 and several of its client pro-
teins, including p70S6K [2,12,15]. Fig. 2D reports the immunoblot analysis
Fig. 1. Effect of PF4708671 and LY294002 on scramble and sh-TRAP1 HEK293 cells during wound healing. A, B, E, F) Time-lapse acquisitions of untreated (A, E), PF4708671 (B) and
LY294002 (F) treated cells, immediately after thewound (T0) and 12, 16 and24 h after (T12h, T16h and T24h). The occupation rate of empty space, evaluated as the ratio between average
distance between the two edges at each time point (Lti) and the samedistance immediately after the scratch (Lt0), is reported as a function of time in C) andG) for scramble (blue) and sh-
TRAP1 (red) HEK293 cells, by using time points corresponding to snapshots taken at 2 hour intervals up to 24 h after the wound. Open symbols are used for cultures in the presence of
20 μM PF4708671 (C) and 10 μM LY294002 (G); closed symbols are used for untreated cultures. D) HEK293 sh stable clones were treated with indicated concentrations of PF4708671
for 1 h. Total lysates were separated by SDS-PAGE and immunoblotted with the indicated antibodies. Images are representative of three independent experiments.
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the densitometric analysis reported in Supplementary Table 1. Remark-
ably, themajority of TRAP1-upregulated tumours exhibited the downreg-
ulation of AKT (10/14 cases). Phosphorylation levels were also assessed,
with 12/14 TRAP1-upregulated tumours exhibiting the downregulation
of phospho-AKT, as conﬁrmed by the χ2 test (p b 0.01).
3.3. Downstream effects of TRAP1-mediated regulation of AKT/p70S6K
The AKT/p70S6K pathway is considered an important player in tu-
mour cell biology, since it is known to promote cell cycle progression,
cell survival, and tumour cell invasion [20]. The latter can be eitherdue to cytoskeleton remodelling, induction of epithelial–mesenchymal
transition (EMT) [21], or metabolic reprogramming.
To evaluate whether AKT/p70S6K pathway regulation by TRAP1
inﬂuences the observed cell migratory behaviour through cytoskele-
ton organization and/or focal adhesion expression, we analysed
actin and paxillin distribution by immunoﬂuorescence. Results did
not show any difference between scramble and sh-TRAP1 cells
(Fig. 3A–B). The expression levels of the two proteins were also ob-
served by immunoblot analysis performed in HEK293 stable clones,
with comparable results (Fig. 3C). Our data suggest that TRAP1
does not affect actin cytoskeleton neither cell–matrix adhesion in
our cellular system.
Fig. 2. TRAP1 regulates AKT expression. A) Total lysates obtained from HCT116 cells transfected for 72 h with non-targeted control siRNA or TRAP1-directed siRNA and from HCT116 and
HEK293 sh stable cloneswere separated by SDS-PAGE and immunoblottedwith the indicated antibodies. Numbers indicate densitometric band intensities, which have been calculated by
assuming protein levels of the control equal to 1. Images are representative of three independent experiments. B) Real-time RT-PCR analysis of single AKT isoform mRNA expression in
HCT116 and HEK293 stable TRAP1 KD cells (sh-TRAP1). All data are expressed as mean with SEM from three independent experiments with technical triplicates each. The p-values indi-
cate the statistical signiﬁcance between relative expression levels. Dashed line indicates expression level of scramble controls. C) sh-TRAP1 and scramble HEK293 cells were transfected
with TRAP1-myc and Δ1-59-myc expression vectors (pcDNA 3.1 vector was used as control). Total cell lysates were harvested after 48 h from transfection, separated by SDS-PAGE and
immunoblotted with the indicated antibodies. Numbers indicate densitometric band intensities, which have been calculated by assuming protein levels of the control (scramble) equal
to 1. Images are representative of three independent experiments. D) Total cell lysates from 14 human CRCs (T) and the respective non-inﬁltrated peritumoural mucosas (M) were sep-
arated by SDS-PAGE and immunoblotted with indicated antibodies.
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AKT, the downstream target p70S6K is directly involved in repression of
E-Cadherin, a transmembrane protein involved in cell adhesion [22],
whose downregulation is considered a hallmark of EMT, typically asso-
ciated with cancer progression and metastasis [23]. p70S6K induction
can induce the expression of the transcription factor Snail through anunknown mechanism, with consequent downregulation of E-Cadherin
[22]. Therefore, we questioned whether this pathway is conserved in
our cellular system and whether the observed differences in cell migra-
tion are due to E-Cadherin expression regulation. qPCR and immunoblot
analyses (Fig. 4A-B) show no changes of Snail mRNA and protein levels
in sh-TRAP1 HEK293 cells, whereas sh-TRAP1 HCT116 cells show a
Fig. 3. TRAP1 expression does not inﬂuence cytoskeleton organization and paxillin distribution. A, B) F-actin and paxillin spikeswere visualized in scramble and sh-TRAP1HEK293 cells by
immunoﬂuorescence staining (see Materials and methods). C) HEK293 sh stable clone total lysates were separated by SDS-PAGE and immunoblotted with the indicated antibodies.
Numbers indicate densitometric band intensities, which have been calculated by assuming protein levels of the control (scramble) equal to 1. Images are representative of three indepen-
dent experiments.
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niﬁcant change of E-Cadherin expression in HCT116 cells upon TRAP1
KD, as shown by qPCR (Fig. 4C), immunoblot (Fig. 4D) and immunoﬂu-
orescence (Fig. 4E),while a decrease of E-CadherinmRNA is observed in
HEK293 cells upon both siRNA and shRNA-mediated TRAP1 silencing
(Fig. 4C); however, as shown in Fig. 4C, HEK293 stable KD clones (sh-
TRAP1) contain very low level of E-Cadherin when compared to
HCT116 cells, to such an extent to be undetectable by immunoblot
and immunoﬂuorescence analyses (data not shown). These results sug-
gest that the observed effects of TRAP1 on cell motility are independent
from the regulation that the AKT/p70S6K axis exerts on actin cytoskele-
ton dynamics and EMT; however, although a possible role of AKT in EMTFig. 4. Correlation between TRAP1 and Snail gene expression and effects of AKT/p70s6k pathw
HCT116 and HEK293 sh stable clones. All data are expressed as mean with SEM from three ind
signiﬁcance between relative expression levels. Dashed line indicates expression level of scram
PAGE and immunoblottedwith the indicated antibodies. Numbers indicate densitometric band i
equal to 1. C) Real-time RT-PCR analysis of E-CadherinmRNA expression in HEK293 sh stable clo
transfection. All data are expressed as mean with SEM from three independent experiments
relative expression levels. Dashed line, dark grey line and light grey line indicate reference
HEK293 sh-TRAP1 respectively. D) HCT116 sh stable clone total lysates were separated by SDS-
band intensities, which have been calculated by assuming protein levels of the control (scram
HCT116. All images are representative of three independent experiments.programme upon TRAP1 KD is supported by E-Cadherin modulation in
HEK293 cell, these ﬁndings require further study in cellmodels inwhich
the role of the AKT/p70S6K pathway in the EMT programmehas already
been assessed.
To complete our analysis of possible mechanisms involved in TRAP1
control of cell migration,we focused on the regulation ofmetabolic pro-
cesses by TRAP1 and analysed their correlation with cell migration. To
this aim, we withdraw from culture medium glutamine (Gln), which
is an important biosynthetic amino acid source, especially in cells with
high energy demands for the synthesis of large amounts of proteins
and nucleic acids. The results of these experiments show that Gln re-
moval causes a reduction of cell motility, with effects being particularlyay on E-Cadherin expression. A) Real-time RT-PCR analysis of Snail mRNA expression in
ependent experiments with technical triplicates each. The p-values indicate the statistical
ble controls. B) HCT116 and HEK293 sh stable clone total lysates were separated by SDS-
ntensities,which havebeen calculatedby assumingprotein levels of the control (scramble)
nes and siRNA-mediated TRAP1 interfered HEK293 andHCT116 cells, harvested 96 h after
with technical triplicates each. The p-values indicate the statistical signiﬁcance between
expression levels of the scramble controls for HCT116 siTRAP1, HEK293 siTRAP1 and
PAGE and immunoblotted with the indicated antibodies. Numbers indicate densitometric
ble) equal to 1. E) Confocal microscopy analysis of E-Cadherin in scramble and sh-TRAP1
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cell migration observed upon TRAP1 KD under basal conditions.
Consistently, Gln deprivation reduces phosphorylation of p70S6K
(Fig. 5D), compromising cell motility in TRAP1 KD, addicted to the
p70S6K pathway.
Taken together, these results suggest that TRAP1 is an important
regulator of AKT/p70S6K activity, through the regulation of their ex-
pression; this, in turn, confers resistance to nutrient deprivation and
to p70S6K inhibitory drugs, thus enabling cell motility under condition
in which it would be normally impaired.3.4. TRAP1 regulates genes involved in cell movement and metastases
To further evaluate the inﬂuence of TRAP1 on the migratory pheno-
type, we took advantage of a whole genome gene expression proﬁling
recently performed in HCT116 sh-TRAP1 stable clones ([10]; Array
Express, accession number E-MTAB-2500). This allowed the identiﬁca-
tion of 504 genes signiﬁcantly modulated in TRAP1-silenced cells
(p b 0.001), with 246 up- and 258 down-regulated. The analysis of the
dataset with the Ingenuity Pathway Analysis identiﬁed cell movement
among the top 5 predicted biofunctions [10]. In this context, 35 up-
and 33 down-regulated genes were found to be associated with cell
movement (Supplementary Table 2), 3 of them (Sox4, F3 and PRSS3)
with a cutoff value of fold change N3. A schematic representation of
interconnecting pathways is reported in Fig. 6A. The expression of
the three genes was validated by qPCR, and Sox4 and F3 conﬁrmed
their transcriptional regulation in HCT116 upon TRAP1 interference
(Fig. 6B). Among those, the regulation of F3/Tissue Factor, a gene that
plays an important role in tissue repair, inﬂammation, angiogenesis,
and tumour metastasis [24], was also conﬁrmed in HEK293 cells, in
which TRAP1 downregulation yields a signiﬁcant decrease in F3
mRNA levels.Fig. 5. Effect of glutamine deprivation on scramble and sh-TRAP1 HEK293 cells in wound hea
immediately after the wound (T0), and after 12, 16 and 24 h (T12h, T16h and T24h). The occu
two edges at each time point (Lti) and the same distance immediately after the scratch (Lt0)
cells by using time points corresponding to snapshots taken at 2 hour intervals up to 24 h af
are used for untreated cultures. D)HEK293 sh stable cloneswere cultured in a Gln deprivedmed
with the indicated antibodies. Images are representative of two independent experiments.3.5. TRAP1 expression and metastatic dissemination in human CRCs
It has been recently shown that TRAP1 promotes metastatic dissem-
ination in human ESCC [11]. To evaluate this correlation in CRC, we
analysed a subset of 34 TRAP1-positive tumours that includes those
characterized for AKT expression/phosphorylation (Fig. 2D). TRAP1-
positive tumours were deﬁned as those in which TRAP1 expression
levels had increased at least threefold in comparison to the correspond-
ing non-inﬁltrated peritumoural mucosa. These preliminary analyses
showed that 41% (14/34 cases) of TRAP1-positive tumours produce dis-
tant metastases, thus suggesting a correlation between TRAP1 expres-
sion and metastatic dissemination in CRC. Among those, 42% of
TRAP1-positive, AKT-negative tumours (5/12 cases) produce distant
metastases, conﬁrming that TRAP1 may contribute to the metastatic
phenotype even in tumours in which the AKT pathway has been
repressed.4. Discussion
Cancer is essentially a disease in which cells have lost their normal
checks on cell proliferation. Consequently, tumour cells often display
fundamental changes in pathways of energy metabolism and nutrient
uptake that places an inherent challenge for malignant cells, which
must set up strategies tomaintain cellular bioenergetic balancewithout
affecting cell growth, proliferation, or viability. These metabolic adapta-
tions must meet three crucial requirements: increased energy produc-
tion, sufﬁcient macromolecular biosynthesis and maintenance of
redox balance. Recent advances in TRAP1 biology have shown how
TRAP1 functions as a network hub protein, involved in all these cellular
processes. In fact, TRAP1 i) contributes to the regulation ofmitochondri-
al physiology through an interaction and regulation of respiratory com-
plexes [3–5]; ii) is part of a pro-survival signalling pathway aimed atling assay. A, B) Time-lapse acquisition of untreated (A) and glutamine deprived (B) cells
pation rate of empty space, evaluated as the ratio between average distance between the
, is reported as a function of time in C) for scramble (blue) and sh-TRAP1 (red) HEK293
ter the wound. Open symbols are used for glutamine-deprived cultures; closed symbols
ium for the indicated times. Total lysateswere separated by SDS-PAGE and immunoblotted
Fig. 6. TRAP1 expression modulates genes involved in cell movement. A) Schematic representation of the transcriptional interactions among 3 cell movement-related genes regulated in
sh-TRAP1 cells according to the whole genome gene expression analysis and conﬁrmed by subsequent real time validation analysis (query genes, visualized in red when upregulated,
green when downregulated). Transcriptional interactions from IPA software. B) Real-time RT-PCR analysis of Sox4, F3 and PRSS3 mRNA expression in HCT116 and HEK293 TRAP1 stably
interfered clones. All data are expressed as mean with SEM from three independent experiments with technical triplicates each. The p-values indicate the statistical signiﬁcance between
relative expression levels. Dashed line indicates expression level of scramble controls.
2577I. Agliarulo et al. / Biochimica et Biophysica Acta 1853 (2015) 2570–2579evading the toxic effects of oxidants and anticancer drugs and plays
a role in protecting mitochondria against apoptotic stimuli [25]; and
iii) controls protein homeostasis through a direct involvement in the
regulation of protein synthesis and degradation [2,12,15]. Whether its
roles in such processes are uniformly oncogenic or not is now matter
of debate. Yoshida and colleagues [4] propose a more subtle distinction
of the role of thismitochondrial chaperone in regulating cellular metab-
olism and impacting tumourigenesis. They have reported an inverse
correlation between TRAP1 expression and tumour stage in cervical,
bladder, and clear cell renal cell carcinoma and that TRAP1 silencing in
several cell lines, including HCT116, HEK293 and Caki-1, resulted in in-
creased cell migration and invasion. Conversely, it has been reported
that TRAP1 KD suppressed cell migration in PC3 prostate cancer and
LN229 glioblastoma cells [8]. In this article, we have demonstrated
that TRAP1 affects cell migration through a regulation of the AKT/
p70S6K pathway by reducing protein expression of AKT, as previously
shown for p70S6K [15]. This confers to TRAP1 KD cells higher migratory
potential under condition of full nutrient availability and in the absence
of cellular stress. However, in low TRAP1 background, cells seem to be
addicted to the activation of this pathway, as demonstrated by stronger
inhibition of cell migration in sh-TRAP1 cells upon treatment with
PF4708671, which inhibits p70S6K, or PIK90, which inhibits PI3K.
Analogously, glutamine deprivation profoundly affects the ability
of cells to migrate in low TRAP1 background, whereas motility of
TRAP1 expressing cells is marginally impaired. The observed high mo-
tile behaviour in low TRAP1 background is therefore p70S6K- and
glutamine-dependent. Accordingly, Caino et al. [8] showed that mito-
chondrial HSP90s, including TRAP1, are crucial for tumour cell motility
in condition of poor nutrient availability. Functionally, this yields
enhanced tumour cell invasion, metastatic dissemination to the bone
or the liver in mouse models of disease, and shortened overall survival
in patients with non-small cell lung cancer. Consistently, our prelimi-
nary observation shows high tendency of TRAP1-positive CRCs to
produce distant metastases, despite low AKT expression. Conversely,in the absence of metabolic stress, cells most rely on AKT/p70S6K
pathway for cell motility. Interestingly, it has been shown that cells ex-
pressing constitutively active AKT are highly sensitized to cell death in-
duced by nutrient and growth factor deprivation [26]. In this view,
TRAP1 expression could represent a mechanism of resistance adopted
by cancer cells when nutrient scarcity requires downregulation of the
AKT pathway.
According to the classical multistep model, metastases generate
from tumour cells that are able to inﬁltrate vessels, survive to circulation
in the blood stream and colonize new sites. To do this, cells must under-
go severalmorphologic andmetabolic changes that go under the deﬁni-
tion of epithelial to mesenchymal transition. In this context, it has been
reported that p70S6K is involved in the regulation of the Snail gene [22].
We have therefore analysed the expression of Snail and E-Cadherin in
two different cell models, ﬁnding that a slight regulation in the expres-
sion of both genes is detectable upon TRAP1KD, although this seems not
to be themainmechanism responsible for the changes in themotile be-
haviour of these cells. Conversely, we demonstrated, at least in our ex-
perimental systems, a prevalent function of metabolic balance for the
TRAP1-dependent regulation of the AKT/p70S6K pathway. Possibly,
more suitable experimental systems, in which many data already con-
ﬁrmed the causal correlation between cell migration, EMT and the
PI3K/AKT/p70S6K pathway, will provide further insights into TRAP1
role in metastatic dissemination. Of note, Liu et al. [9] found that in
two different cell lines (lung adenocarcinoma cells and breast cancer
cells), the expression of TRAP1 is inversely related to the expression of
genes involved in metastasis, suggesting that, while induction of
TRAP1 expression promotes cell proliferation and tumour growth
through the TNF pathway, its down-regulation may lead to decreased
proliferation and increase of metastatic potential. This seems to be me-
diated by higher expression of genes promoting cell–cell and cell–ma-
trix adhesion like cadherins, which are known to play critical roles in
the processes of invasion and metastasis [27]. Moreover, Kubota et al.
[28] have reported that siRNA-mediated knockdown of TRAP1 in a
2578 I. Agliarulo et al. / Biochimica et Biophysica Acta 1853 (2015) 2570–2579neuronal cell line resulted in down-regulation of N-cadherin and affect-
ed the adhesive properties of the cells.
We also analysed the gene expression pattern of HCT116 cells fol-
lowing TRAP1 downregulation, and found several genes involved in
cell motility and EMT to be differentially regulated in TRAP1 KD cells.
In particular, we have analysed the expression of SOX4, F3 and PRSS3.
SOX4, which is considered themaster regulator of EMT [29], is substan-
tially upregulated in HCT116 sh-TRAP1 cells. SOX4 KD has been related
to reduced tumour cell migration, invasion, in vivo tumourigenesis and
metastasis in hepatocellular carcinoma [30], and overexpression of nu-
clear SOX4 was signiﬁcantly correlated with invasion, metastasis and
stage in CRC patients [31]. Conversely, we found the F3/Tissue Factor
gene two-fold downregulated in the highly motile sh-TRAP1 cells. The
F3 gene encodes for the Tissue Factor protein, which is well known as
the primary regulator of coagulation [32], but it also plays an important
role in angiogenesis [33], contributing to tumour progression.Moreover,
upregulation of vascular endothelial cell growth factor (VEGF) by the
Tissue Factor cytoplasmic domain has been suggested [34], along with
contribution to cell migration via direct interaction with Actin binding
protein 280 [35]. Interestingly, F3 is the only gene that we have found
signiﬁcantly downregulated in both cell lines in which TRAP1 has been
silenced. Notably, deprivation of amino acids induces VEGF expression
in human tumours of different lineages through the GCN2/ATF4 path-
way [36],whichwehave previously shown to be regulated by TRAP1 [2].
Taken together, these results conﬁrm a dual role of TRAP1 in the reg-
ulation of cell motility, enabling cell movement under limiting condi-
tions, while possibly reducing the maximum migratory potential of
cells when plenty of energy source are available. Targeting TRAP1 may
thus enhance the efﬁcacy of antimetastatic treatments selectively for
those cancers inwhich signalling pathwayby this chaperone contributes
to resistance to tumour-suppressive mechanisms and metabolic stress.
5. Conclusions
The inhibition of a single protein regulating multiple signal trans-
duction pathways in cancer cells is an attractive therapeutic approach
in humanmalignancies. For this reason, Hsp90 chaperone family mem-
bers are unique cancer targets, since they are required for the folding
and stability of many oncogenic signalling proteins. The therapeutic se-
lectivity of Hsp90 inhibitors results from the presence of a high-afﬁnity,
activated form of Hsp90 in tumours, whereas the Hsp90 in normal tis-
sues is a low-afﬁnity, inactive form [37]. Similarly, TRAP1 has been pur-
sued as a promising target for novel mitochondriotopic/therapeutic
strategies for its cytoprotective and antiapoptotic roles in cancer cells
[6] and other diseases [38], although recent advances in TRAP1 biology
suggest to be prudent [25]. In this article, we have shown that TRAP1
expression also inﬂuences tumour cell's migratory potential, which
raises new questions to answer in the near future in order to select
TRAP1 as predictive biomarker of cancer progression and metastasis.
An anti-TRAP1 therapeutic approach could be effective in counteracting
resistance to anti-AKT strategies.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2015.05.034.
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